Skip to main content
OpenTrials
Recruiting

NCT Number: NCT01042548

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum

The current study is a case control study involving comparisons of tissue interstitial fluid from breast cancer and adjacent non-cancerous tissue as well as that from benign breast lesion and its adjacent non-diseased tissue for a distinguishable breast cancer profile. The purpose of this research is to collect fresh breast nodule/cancer and surrounding non-cancerous tissue for proteomic studies of the interstitial fluid to identify a profile distinguishing breast cancer which will also permit future research on stored interstitial fluid, blood or tissue samples. Specific markers identified from interstitial fluid study will be investigated in blood samples to develop serum markers for breast cancer diagnosis and prognosis. Additionally, we will perform both prospective and retrospective research on breast cancer involving clinical, demographic, epidemiologic information, treatment, follow-up and outcomes on breast nodule/cancer cases collected.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

UPMC St. Margaret

Pittsburgh, Pennsylvania, 15215, United States

Location status: Recruiting

Location contact

Laura Chiesa

CONTACT

[email protected]

412-831-1320

Min Sun, MD, PhD

CONTACT

Min Sun, MD, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All subjects ≥ 18 years of age undergoing surgery for indeterminate breast nodules, breast tissue reduction, prophylactic mastectomy, and all subjects with newly diagnosed invasive breast cancer will be eligible to participate. If invasive breast cancer or suspicion of invasive breast cancer, target lesion must measure ≥ 1.0 cm on breast imaging before core biopsy.

Exclusion criteria

  • Anyone < 18 years of age.
  • Multiple synchronous primary malignancies from different organ systems.

Study contacts

Contact information is provided by the study sponsor or research team.

Laura Chiesa

CONTACT

[email protected]

412-831-1320

Min Sun, MD, PhD

CONTACT

[email protected]

412-781-3744

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Collaborators

  • David Scaife Foundation

Registry information

Important dates

Study start
2010
Primary completion
2030
Study completion
2030
First posted
Jan 5, 2010
Registry last updated
May 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.